Ignite Creation Date:
2025-12-25 @ 2:53 AM
Ignite Modification Date:
2025-12-26 @ 1:34 AM
Study NCT ID:
NCT04352933
Status:
UNKNOWN
Last Update Posted:
2020-05-13
First Post:
2020-04-07
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
PROLIFIC ChemoprophylaxisTrial (COVID-19)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'Double-blind'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1000}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2020-05-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-05', 'completionDateStruct': {'date': '2021-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-05-11', 'studyFirstSubmitDate': '2020-04-07', 'studyFirstSubmitQcDate': '2020-04-15', 'lastUpdatePostDateStruct': {'date': '2020-05-13', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-04-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-10-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time to positive COVID-19 disease', 'timeFrame': 'Assessed up to 90 days', 'description': 'Time taken for incidence of COVID-19 disease between Hydroxychloroquine and placebo arms'}], 'secondaryOutcomes': [{'measure': 'Number of COVID-19 test positive cases', 'timeFrame': 'Assessed up to 90 days', 'description': 'Number of COVID-19 symptoms based on clinical guidelines and test positive infections per study arm'}, {'measure': 'Number of COVID-19 serological test positive cases', 'timeFrame': 'Assessed up to 90 days', 'description': 'Number of test positive COVID-19 serological test positive cases per study arm'}, {'measure': 'Severity of COVID-19 disease between each arm', 'timeFrame': 'Assessed up to 90 days', 'description': 'Severity based on hospitalisation'}, {'measure': 'Number of common COVID-19 complications between each arm', 'timeFrame': 'Assessed up to 90 days', 'description': 'Number of common COVID-19 complications between arms'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['SARS-CoV-2', 'Coronavirus', 'COVID-19', 'chemoprophylaxis', 'Hydroxychloroquine'], 'conditions': ['COVID-19']}, 'descriptionModule': {'briefSummary': 'The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to cope with the increased demand. The availability of personal protective equipment is limited and reports of high risk procedures such as aerosol generating procedures (e.g. intubation for the sickest patients) is a source of great concern for infection transmission. Frontline NHS staff with direct patient contact have the highest likelihood of exposure to SARS-CoV-2 and development of COVID-19 disease. Efforts to protect these workers from development of COVID-19, using drugs to prevent the disease, require urgent evaluation.', 'detailedDescription': 'The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to cope with the increased demand. The availability of personal protective equipment is limited and reports of high risk procedures such as aerosol generating procedures (e.g. intubation for the sickest patients) is a source of great concern for infection transmission. Frontline NHS staff with direct patient contact have the highest likelihood of exposure to SARS-CoV-2 and development of COVID-19 disease. Efforts to protect these workers from development of COVID-19, using drugs to prevent the disease, require urgent evaluation.\n\nThis trial will be a double-blind, randomized, placebo-controlled trial in a cohort of frontline healthcare workers, who will potentially be exposed to SARS-CoV-2. Eligible participants will be frontline NHS workers aged 18 to 70 years who work in a healthcare setting with direct patient care. Participants will be randomised to one of 3 arms and receive either: (1) Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo; (2) Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, or (3) placebo (daily and weekly).\n\nParticipants will be reviewed at an interim visit 6 weeks after baseline and again and the end of the study treatment in 90 days (approximately 3 months) after randomization. Participants will also complete brief questions about their health weekly while on treatment (remotely, via app/web/phone-based interface).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\nTo be included in the trial the participant MUST:\n\n1. Have given written informed consent to participate\n2. Be aged 18 years to 70 years\n3. Not previously have been diagnosed with COVID-19\n4. Work in a high-risk secondary or tertiary healthcare setting (hospitals accepting COVID-19 patients) with direct patient-facing care\n\nExclusion Criteria:The presence of any of the following will mean participants are ineligible:\n\n1. Known COVID-19 positive test at baseline (if available)\n2. Symptomatic for possible COVID-19 at baseline\n3. Known hypersensitivity reaction to HCQ, chloroquine or 4-aminoquinolines\n4. Known retinal disease\n5. Known porphyria\n6. Known chronic kidney disease (CKD; eGFR\\<30ml/min)\n7. Known epilepsy\n8. Known heart failure or conduction problems\n9. Known significant liver disease (Gilbert's syndrome is permitted)\n10. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency\n11. Currently taking any of the following contraindicated medications:\n\n 1. Digoxin\n 2. Chloroquine\n 3. Halofantrine\n 4. Amiodarone\n 5. Moxifloxacin\n 6. Cyclosporin\n 7. Mefloquine\n 8. Praziquantel\n 9. Ciprofloxacin\n 10. Clarithromycin\n 11. Prochlorperazine\n 12. Fluconazole\n12. Currently taking hydroxychloroquine or having a clinical indication for taking hydroxychloroquine\n13. Currently breastfeeding\n14. Unable to be followed-up during the trial\n15. Current or future involvement in the active treatment phase of other interventional research studies (excluding observational/non-interventional studies) before study follow-up visit\n16. Not able to use or have access to a modern phone device/web-based technology\n17. Any other clinical reason which may preclude entry in the opinion of the investigator"}, 'identificationModule': {'nctId': 'NCT04352933', 'briefTitle': 'PROLIFIC ChemoprophylaxisTrial (COVID-19)', 'organization': {'class': 'OTHER', 'fullName': 'Cambridge University Hospitals NHS Foundation Trust'}, 'officialTitle': 'ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)', 'orgStudyIdInfo': {'id': 'PROLIFIC2020 (A095583)'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Hydroxychloroquine - Daily dosing', 'description': 'Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo, for approximately 90 days.\n\nRoute: Oral. Pharmaceutical form: Tablet', 'interventionNames': ['Drug: Hydroxychloroquine - Daily dosing']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Hydroxychloroquine - Weekly dosing', 'description': 'Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, for approximately 90 days.\n\nRoute: Oral. Pharmaceutical form: Tablet', 'interventionNames': ['Drug: Hydroxychloroquine - Weekly Dosing']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo arm - 2 tablets twice daily for first 2 days (loading phase), followed by 1 tablet every day for 90 days plus 2 tablets every 7th day, for approximately 90 days.\n\nRoute: Oral. Pharmaceutical form: Tablet', 'interventionNames': ['Other: Matched Placebo Hydroxychloroquine']}], 'interventions': [{'name': 'Hydroxychloroquine - Daily dosing', 'type': 'DRUG', 'description': 'Active HCQ:\n\nDays 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (\\~3 months),\n\nMatched Placebo HCQ:\n\nDays 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\\~3 months)', 'armGroupLabels': ['Hydroxychloroquine - Daily dosing']}, {'name': 'Hydroxychloroquine - Weekly Dosing', 'type': 'DRUG', 'description': 'Active HCQ:\n\nDays 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\\~3 months)\n\nMatched Placebo HCQ:\n\nDays 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\\~3 months)', 'armGroupLabels': ['Hydroxychloroquine - Weekly dosing']}, {'name': 'Matched Placebo Hydroxychloroquine', 'type': 'OTHER', 'description': 'Matched placebo HCQ - daily dosing:\n\nDays 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\\~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\\~3 months)', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'CB2 0QQ', 'city': 'Cambridge', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Cambridge University Hospitals NHS Foundation Trust', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}], 'centralContacts': [{'name': 'Ella James, PhD', 'role': 'CONTACT', 'email': 'ella.james@addenbrookes.nhs.uk', 'phone': '01223 349762'}, {'name': 'Heike Templin', 'role': 'CONTACT', 'email': 'heike.templin@addenbrookes.nhs.uk', 'phone': '01223 250874'}], 'overallOfficials': [{'name': 'Joseph Cheriyan, MBCHB, FRCP', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Cambridge University Hospitals NHS Foundation Trust'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Cambridge University Hospitals NHS Foundation Trust', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Dr', 'investigatorFullName': 'Joseph Cheriyan, MD', 'investigatorAffiliation': 'Cambridge University Hospitals NHS Foundation Trust'}}}}